| Literature DB >> 34108497 |
Chaiwat Washirasaksiri1, Weerachai Srivanichakorn2,3, Ian F Godsland4, Chayanis Kositamongkol1, Suwat Chariyalertsak5, Pattapong Kessomboon6, Sawitri Assanangkornchai7, Surasak Taneepanichskul8, Nareemarn Neelapaichit9, Pochamana Phisalprapa1, Desmond G Johnston4, Nick S Oliver4, Wichai Aekplakorn10.
Abstract
Internationally, studies have shown associations between lipids and glycemia; however, whether the link varies by gender and population has been rarely examined. We investigated relationships between glycemia and HDL- and Non-HDL-cholesterol and their modification by gender. We undertook a cross-sectional analysis from the National Health Examination Survey for Thailand (NHES-Thailand) and the Health Survey for England (HS-England) in adults aged 18-75 year. Glycaemia was assessed by FPG in Thailand and by HbA1c in the UK. In population- and gender-stratified analyses, the relationships between glycemia and lipids were explored. A total of 15,145 Thai and 3484 UK adults with blood measurement were included. The prevalences of prediabetes were: in NHES-Thailand, 16% (SE = 0.004), based on FPG (5.6 to < 7.0 mmol/L) and in HS-England, 19% (0.007) based on HbA1c (39 to < 48 mmol/mol). Increasingly abnormal glucose homeostasis was associated with increasing age, adiposity, SBP, proportion of antihypertensive and lipid-lowering agent use and with decreasing HDL-cholesterol. Independent of age, adiposity, smoking, alcohol, physical activity, and lipid and BP lowering drug use, increasing glycemia was associated with decreasing HDL-cholesterol specifically in women with prediabetes (NHES-Thailand, beta-coefficient - 0.07 (95% CI - 0.15, - 0.001) p = 0.04 and HS-England, - 0.03 (- 0.04, - 0.006) p = 0.01). In both populations, among those with prediabetes, increasing glycaemia is associated with an adverse, significant decline in HDL cholesterol, specifically in women. These adverse effects are apparent in widely-differing international populations.Entities:
Year: 2021 PMID: 34108497 PMCID: PMC8190299 DOI: 10.1038/s41598-021-91075-9
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Fasting Plasma Glucose and HbA1c level by glycemic categories in two study populations.
| Parameters | NGH | IGH—mild | IGH—severe | Diabetes | |
|---|---|---|---|---|---|
| FPG < 5.6 | FPG 5.6 to < 6.1 | FPG 6.1 to < 7.0 | Diabetes* | ||
| 74 (0.01) | 11 (0.004) | 5 (0.003) | 10 (0.003) | ||
| Gender** (% (SEP)) | M | 48 (0.01) | 50 (0.02) | 52 (0.03) | 43 (0.02) |
| F | 52 (0.01) | 50 (0.02) | 48 (0.03) | 57 (0.02) | |
| FPG, mmol/L (% ± SEM) | M | 5.0 ± 0.02 | 5.8 ± 0.01 | 6.4 ± 0.02 | 9.0 ± 0.21 |
| F | 4.9 ± 0.01 | 5.8 ± 0.01 | 6.4 ± 0.02 | 9.1 ± 0.14 | |
| HbA1c < 39 | HbA1c 39 to < 42 | HbA1c 42 to < 48 | Diabetes* | ||
| 75 (0.01) | 13 (0.01) | 6 (0.004) | 6 (0.004) | ||
| Gender*** (% (SEP)) | M | 49 (0.01) | 49 (0.02) | 48 (0.03) | 61 (0.04) |
| F | 51 (0.01) | 51 (0.02) | 52 (0.03) | 39 (0.04) | |
| HbA1c, (% ± SEM) (mmol/mol) | M | 5.3 ± 0.01% | 5.8 ± 0.01% | 6.1 ± 0.02% | 7.6 ± 0.2% |
| 34.0 ± 0.1 | 39.8 ± 0.1 | 43.3 ± 0.2 | 59.9 ± 1.7 | ||
| F | 5.3 ± 0.01% | 5.8 ± 0.01% | 6.2 ± 0.01% | 8.1 ± 0.2% | |
| 34.1 ± 0.1 | 39.8 ± 0.1 | 43.5 ± 0.1 | 65.0 ± 2.2 |
FPG and HbA1c are presented as mean ± standard error of mean, SEM (%) and gender proportion as % (standard error of proportion, SEP).
NGH normal glucose homeostasis, IGH impaired glucose homeostasis, NHES-Thailand the National Health Examination Survey for Thailand, HS-England the Health Survey for England, HbA1c hemoglobin A1c, FPG fasting plasma glucose, n the number, M male, F female, p p value.
*Diabetes is defined by Participants with FPG ≥ 7.0 mmol/L (Thai) and/or HbA1c ≥ 48 mmol/mol (UK) and/or current on glucose lowering agent and/or self-reported previous diagnosis by doctor.
**Significant variation between gender proportion p = 0.01.
***Significant variation between gender proportion p = 0.02.
Crude means and proportion of individual characteristics and lipid level by glycemic categories in two study populations.
| Parameters | NHES-THAILAND | HS-ENGLAND | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| NGH | IGH—mild | IGH—severe | Diabetes | p* | NGH | IGH—mild | IGH—severe | Diabetes | p* | |
| Male | 41.5 ± 0.3 | 46.8 ± 0.7 | 50.3 ± 0.9 | 52.7 ± 0.7 | < 0.001 | 40.6 ± 0.5 | 53.7 ± 1.0 | 56.2 ± 1.2 | 56.6 ± 1.2 | < 0.001 |
| Female | 42.2 ± 0.3 | 48.3 ± 0.7 | 49.7 ± 1.1 | 53.5 ± 0.6 | < 0.001 | 41.1 ± 0.5 | 54.4 ± 0.9 | 59.2 ± 1.1 | 56.4 ± 1.5 | < 0.001 |
| Male | 23.5 ± 0.1 | 24.6 ± 0.3 | 25.0 ± 0.3 | 25.0 ± 0.2 | < 0.001 | 26.5 ± 0.2 | 28.6 ± 0.3 | 29.2 ± 0.4 | 30.6 ± 0.7 | < 0.001 |
| Female | 24.5 ± 0.1 | 25.8 ± 0.2 | 26.6 ± 0.4 | 26.4 ± 0.2 | < 0.001 | 26.3 ± 0.2 | 28.7 ± 0.4 | 29.4 ± 0.6 | 33.1 ± 0.8 | < 0.001 |
| Male | 82.2 ± 0.3 | 85.6 ± 0.7 | 86.8 ± 0.9 | 87.7 ± 0.6 | < 0.001 | 93.8 ± 0.5 | 101.4 ± 0.9 | 104.0 ± 1.2 | 106.1 ± 1.6 | < 0.001 |
| Female | 80.4 ± 0.2 | 84.4 ± 0.6 | 86.0 ± 1.0 | 87.7 ± 0.5 | < 0.001 | 84.7 ± 0.4 | 92.5 ± 0.9 | 95.7 ± 1.3 | 102.2 ± 1.6 | < 0.001 |
| Male | 7 (0.01) | 11 (0.01) | 20 (0.03) | 31 (0.02) | < 0.001 | 7 (0.01) | 23 (0.03) | 22 (0.04) | 52 (0.05) | < 0.001 |
| Female | 7 (0.01) | 11 (0.01) | 20 (0.03) | 31 (0.02) | < 0.001 | 6 (0.01) | 18 (0.02) | 32 (0.04) | 52 (0.06) | < 0.001 |
| Male | 4 (0.004) | 6 (0.01) | 10 (0.02) | 26 (0.02) | < 0.001 | 5 (0.01) | 20 (0.03) | 34 (0.05) | 68 (0.05) | < 0.001 |
| Female | 6 (0.004) | 12 (0.01) | 16 (0.02) | 35 (0.02) | < 0.001 | 4 (0.01) | 13 (0.02) | 24 (0.04) | 58 (0.06) | < 0.001 |
| Male | 5 (0.01) | 20 (0.03) | 34 (0.05) | 68 (0.05) | < 0.001 | 5 (0.01) | 20 (0.03) | 34 (0.05) | 68 (0.05) | < 0.001 |
| Female | 5 (0.01) | 20 (0.03) | 34 (0.05) | 68 (0.05) | < 0.001 | 5 (0.01) | 20 (0.03) | 34 (0.05) | 68 (0.05) | < 0.001 |
| Male | 59 (0.01) | 67 (0.02) | 59 (0.03) | 50 (0.03) | < 0.001 | 89 (0.01) | 86 (0.03) | 84 (0.04) | 75 (0.05) | < 0.001 |
| Female | 26 (0.01) | 23 (0.02) | 22 (0.03) | 14 (0.02) | < 0.001 | 84 (0.01) | 77 (0.03) | 78 (0.04) | 64 (0.06) | < 0.001 |
| Male | 82 (0.01) | 81 (0.02) | 84 (0.02) | 79 (0.02) | 0.3 | 68 (0.02) | 54 (0.04) | 51 (0.05) | 37 (0.05) | < 0.001 |
| Female | 82 (0.01) | 85 (0.02) | 84 (0.02) | 81 (0.02) | 0.1 | 53 (0.02) | 46 (0.03) | 39 (0.04) | 27 (0.05) | < 0.001 |
| Male | 3.85 ± 0.03 | 3.98 ± 0.07 | 4.10 ± 0.08 | 3.91 ± 0.08 | 0.04 | 3.69 ± 0.04 | 4.02 ± 0.08 | 3.97 ± 0.12 | 3.20 ± 0.12 | 0.2 |
| Female | 3.83 ± 0.02 | 4.12 ± 0.06 | 4.02 ± 0.08 | 3.95 ± 0.06 | 0.001 | 3.33 ± 0.03 | 4.05 ± 0.07 | 3.90 ± 0.10 | 3.56 ± 0.15 | < 0.001 |
| Male | 1.23 ± 0.01 | 1.14 ± 0.02 | 1.16 ± 0.02 | 1.10 ± 0.02 | < 0.001 | 1.42 ± 0.01 | 1.34 ± 0.03 | 1.30 ± 0.04 | 1.18 ± 0.04 | < 0.001 |
| Female | 1.36 ± 0.01 | 1.31 ± 0.02 | 1.28 ± 0.03 | 1.25 ± 0.02 | < 0.001 | 1.69 ± 0.01 | 1.65 ± 0.03 | 1.55 ± 0.04 | 1.34 ± 0.05 | < 0.001 |
HS-England the Health Survey for England, p p value, BMI body mass index, HDL-c High density lipoprotein cholesterol, LDL-c Low density lipoprotein cholesterol.
*Summary statistics for raw data are presented, unstandardized for any between-population differences. Continuous normally-distributed variables; mean ± standard error of mean, Categorical variables; percentage (standard error of the proportion) are shown. NGH; normal glucose homeostasis (FPG < 5.6 mmol/L (Thai) or HbA1c < 5.7% (UK)), IGH-mild; mild impaired glucose homeostasis (FPG 5.6 to < 6.1 mmol/L (Thai) or HbA1c 39 to < 42 mmol/mol (UK)), IGH-severe: severe impaired glucose homeostasis (FPG 6.1 to < 7.0 mmol/L (Thai) or HbA1c 42 to < 48 mmol/mol (UK)), diabetes, FPG ≥ 7.0 mmol/L or HbA1c ≥ 48 mmol/mol and/or currently taking a glucose lowering agent and/or self-reported previous diabetes diagnosis by doctor, the National Health Examination Survey for Thailand.
Regression coefficients (95% CI) of FPG and covariates associated with HDL-c and Non HDL-c by glycemic categories and gender in the Thai National Health Examination Survey.
| NHES-Thailand | Male | Female | ||||||
|---|---|---|---|---|---|---|---|---|
| Overall | NGH | IGH | Diabetes | overall | NGH | IGH | Diabetes | |
| FPG | − 0.005 (− 0.014, 0.005)0.3 | 0.002 (− 0.017, 0.022)0.8 | 0.063 (− 0.011, 0.138)0.09 | 0.011 (− 0.002, 0.023)0.08 | − 0.011 (− 0.017, − 0.004)0.001 | − 0.025 (− 0.045, − 0.005)0.01 | − 0.073 (− 0.150, − 0.0002)0.04 | − 0.002 (− 0.010, 0.006)0.6 |
| Age | − 0.001 (− 0.002, 0.00001)0.05 | − 0.001 (− 0.002, 0.001)0.05 | 0.001 (− 0.001, 0.003)0.1 | 0.001 (− 0.002, 0.005)0.5 | 0.00004 (− 0.001, 0.001)0.9 | − 0.0001 (− 0.001, 0.001)0.8 | 0.002 (− 0.0001, 0.004)0.06 | − 0.0006 (− 0.004, 0.002)0.7 |
| Waist circumference | − 0.008 (− 0.009, − 0.007)<0.001 | − 0.008 (− 0.010, − 0.007)<0.001 | − 0.008 (− 0.011, − 0.006)<0.001 | − 0.004 (− 0.007, − 0.001)0.04 | − 0.007 (− 0.008, − 0.006)<0.001 | − 0.008 (− 0.009, − 0.007)<0.001 | − 0.005 (− 0.007, − 0.003)<0.001 | − 0.006 (− 0.009, − 0.003)<0.001 |
FPG fasting plasma glucose, BMI body mass index, HDL-c high density lipoprotein cholesterol, NGH normal glucose homeostasis (FPG < 5.6 mmol/L), IGH impaired glucose homeostasis (FPG 5.6 to < 7.0 mmol/L), diabetes, FPG ≥ 7.0 mmol/L and/or currently taking a glucose lowering agent and/or self-reported previous diabetes diagnosis by doctor. In addition to those shown, predictor variables included in each multivariable model also included lipid lowering agent use, smoking, alcohol status, total energy intake and physical activity status.
Regression coefficients (95% CI) of HbA1c and covariates associated with HDL-c and Non HDL-c by glycemic categories and gender in the Health Survey for England.
| HS-England | Male | Female | ||||||
|---|---|---|---|---|---|---|---|---|
| Overall | NGH | IGH | Diabetes | Overall | NGH | IGH | Diabetes | |
| HbA1c | − 0.003 (− 0.006, − 0.001)0.008 | 0.005 (− 0.004, 0.013)0.2 | − 0.0003 (− 0.021, 0.021)0.9 | − 0.001 (− 0.005, 0.003)0.5 | − 0.003 (− 0.006, − 0.0004)0.02 | − 0.006 (− 0.014, 0.003)0.1 | − 0.021 (− 0.04, − 0.003)0.02 | 0.002 (− 0.002, 0.006)0.2 |
| Age | 0.004 (0.003, 0.006)<0.001 | 0.005 (0.003, 0.007)<0.001 | 0.002 (− 0.002, 0.007)0.3 | − 0.001 (− 0.006, 0.004)0.7 | 0.009 (0.008, 0.010)<0.001 | 0.010 (0.009, 0.012)<0.001 | 0.008 (0.005, 0.011)<0.001 | 0.0002 (− 0.008, 0.008)0.9 |
| Waist circumference | − 0.010 (− 0.012, − 0.008)<0.001 | − 0.011 (− 0.013, − 0.008)<0.001 | − 0.01 (− 0.013, − 0.006)<0.001 | − 0.007 (− 0.012, − 0.002)0.006 | − 0.014 (− 0.016, − 0.013)<0,001 | − 0.014 (− 0.016, − 0.013)<0.001 | − 0.013 (− 0.016, − 0.011)<0.001 | − 0.006 (− 0.015, 0.003)0.1 |
HbA1c Hemoglobin A1c, BMI body mass index, HDL-c high density lipoprotein cholesterol, NGH normal glucose homeostasis (HbA1c < 5.7%), IGH impaired glucose homeostasis (HbA1c 39 to < 42 mmol/mol), diabetes; HbA1c ≥ 48 mmol/mol and/or currently taking a glucose lowering agent and/or self-reported previous diabetes diagnosis by doctor. In addition to those shown, predictor variables included in each multivariable model also included lipid lowering agent use, smoking, alcohol status, total energy intake and physical activity status.
Figure 1Regression lines fitted to the model-predicted HDL-c concentrations from the models reported in Tables 3 and 4 to illustrate the differences in strengths of association between HDL-c and glycaemia between men and women with impaired glucose homeostasis in the National Health Examination Survey for Thailand ((A), NHES-Thailand) and in the Health Survey for England ((B), HS-England).